Clinical applications - CliniMACS CD34 Reagent System (FDA approved) - Patients

Information for patients

This website is intended for US patients undergoing allogeneic stem cell transplantation in acute myeloid leukemia (AML) and their families. It provides information about the causes of graft-versus-host disease and its prevention by ex vivo T cell depletion.
Note: Are some of the words or abbreviations unfamiliar to you? Definitions of all words marked in green appear if you move your mouse over the word or can be found in the glossary.

This website is not intended to replace conversations with your healthcare team. Your doctor and other healthcare providers are the most valuable resources for answering questions about your disease and ex vivo T cell depletion as method for graft-versus-host disease prophylaxis.

What is AML?

What is AML?

Acute myeloid leukemia (AML) is a type of blood cancer. There are three main types of cells in the blood; red blood cells, white blood cells, and platelets. Normally, white blood cells are responsible for fighting infections and other diseases. read more

What is an allogeneic stem cell transplantation?

What is an allogeneic stem cell transplantation?

Autologous stem cell transplantation may be used as a consolidation therapy. However, allogenic stem cell transplantation is considered to be the best curative treatment option for some AML patients. read more

What is GvHD?

What is GvHD?

Although allogeneic stem cell transplantation is a potentially curative treatment option for AML, it is also associated with the risk of several serious side effects. One major complication is a disease called graft-versus-host disease (GVHD). read more

Contact

Contact information for patients

read more

Glossary

Glossary

read more

Loading...
Your opinion matters

Your opinion matters

Change country

Please select your country to continue